Please login to the form below

Not currently logged in

Royalty Pharma

This page shows the latest Royalty Pharma news and features for those working in and with pharma, biotech and healthcare.

Forest Labs agrees $1.46bn deal to buy Furiex

Forest Labs agrees $1.46bn deal to buy Furiex

Rights to these products will be sold on to Royalty Pharma AG for around $415m, helping to offset the Furiex purchase by around $315m, although Forest said the main Furiex deal

Latest news

  • 2013 - biotech boomed 2013 - biotech boomed

    The $10bn-plus strategic acquisition returned and pharma companies sought to replenish their pipelines.  . ... battle which had seen Elan resort to legal action to fend off hostile bids from US company Royalty Pharma.

  • Royalty Pharma buys bigger Tecfidera interest Royalty Pharma buys bigger Tecfidera interest

    Royalty Pharma has bought an interest in Biogen Idec's much-touted new oral multiple sclerosis (MS) therapy Tecfidera for $510m in cash. ... Royalty Pharma negotiated a similar earn-out agreement with former Fumapharm shareholders in May 2012, paying

  • Perrigo agrees $8.6bn deal to buy Elan Perrigo agrees $8.6bn deal to buy Elan

    Ends months of speculation about fate of Irish pharma company. Speculation about the future of Elan seems to have ended with the news that US generic drugmaker Perrigo has agreed an ... from US company Royalty Pharma.

  • FDA fast-tracks Elan’s Alzheimer’s drug FDA fast-tracks Elan’s Alzheimer’s drug

    These deals have yet to provide Elan with definitive pipeline prospects, and have been roundly criticised by Royalty Pharma – a firm that specialises in buying up intellectual property assets in the ... Royalty's interest in Elan was first noted in

  • Elan blocks Royalty takeover - for now Elan blocks Royalty takeover - for now

    After rejecting Royalty Pharma's bid Elan wants greater clarity on the deal. ... lowball revised tender offer and deliver the company into Royalty Pharma's hands at an unfair and inadequate price.”.

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Acquisition. $244m. Zealand/. Royalty Pharma. Royalty streams and milestones for Soliqua 100/33/. ... So two opportunities here – acquisition of animal health products and out-licensing to Bayer’s pharma business.

  • Deal Watch January 2018

    Collaboration, licence. 310. Immunomedics/ Royalty Pharma. Royalty rights to sacituzumab govitecan (IMMU- 132) across all indications. ... Also in January Immunomedics sold tiered royalty rights on global net sales of its antibody drug conjugate,

  • Deal Watch February 2017 Deal Watch February 2017

    The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... Sale of Priority Review Voucher (PRV). 125.

  • Deal Watch March 2016 Deal Watch March 2016

    Only one other deal had an upfront value of more than $1bn: the sale by UCLA to Royalty Pharma of its royalty rights to Xtandi with a cash payment of ... Research collaboration. $2, 258. UCLA/ Royalty Pharma. Xtandi – androgen receptor inhibitor.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    For an indepth analysis of these deals, read'Pharma deals during November 2014'. ... Omega Pharma / Perrigo. OTC portfolio. Company acquisition. 4, 500. Cystic Fibrosis Foundation /Royalty Pharma.

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...